Imipenem-cilastatin as initial therapy for febrile cancer patients.

Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infec...

Descripción completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Autores principales:	Bodey, G P, Alvarez, M E, Jones, P G, Rolston, K V, Steelhammer, L, Fainstein, V
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 1986
Materias:	Research Article
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC180520/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3532942/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.30.2.211
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!